{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:31:58Z","timestamp":1765175518095,"version":"3.46.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"\n Background<\/jats:title>\n New-onset atrial fibrillation (NOAF) is the most commonly encountered arrhythmia during the course of acute myocardial infarction (AMI) and is independently associated with a worse prognosis.<\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n We aimed to validate the discriminatory performance of cancer antigen-125 (CA-125) in predicting post-AMI NOAF in the Chinese population.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 488 consecutive patients with AMI from 1 January 2020 to 1 January 2022 without a previous history of AF were enrolled in this study. Risk factors for post-AMI NOAF were determined using univariable and multivariable logistic regression analyses. Receiver operating characteristic (ROC) curve analyses were used to evaluate the discrimination performance of different parameters and score models. Area under the curve (AUCs) were compared using\n Z<\/jats:italic>\n tests.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In total, 48 (9.84%) patients developed post-AMI NOAF during hospitalization. The NOAF group was older and had a higher Killip class, B-type natriuretic peptide level, CA-125 level, left atrial diameter, left ventricular end-systolic diameter, CHA\n 2<\/jats:sub>\n DS\n 2<\/jats:sub>\n -VASc (Congestive heart failure, Hypertension, Age \u226575 years [2 points], Diabetes mellitus, Stroke\/transient ischemic attack\/thromboembolism history [2 points], Vascular disease, Age 65\u201374 years, Sex category [female]) score, Global Registry of Acute Coronary Events (GRACE) risk score (RS), and in-hospital mortality, and a lower low-density lipoprotein level, left ventricular ejection fraction, and initial\n \u03b2<\/jats:italic>\n -receptor blocker and angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use (\n P<\/jats:italic>\n \u2009&lt;\u20090.05 vs. the no-NOAF group for all measures). In the multivariate regression analyses, CA-125 remained an independent risk factor for post-AMI NOAF in different models. In the ROC curve analyses, CA-125 (AUC\u2009=\u20090.753, 95% CI: 0.665\u20130.84,\n P<\/jats:italic>\n \u2009&lt;\u20090.001), GRACE RS (AUC\u2009=\u20090.701, 95% CI: 0.593\u20130.809,\n P<\/jats:italic>\n \u2009=\u20090.001), and CHA2DS2-VASc score (AUC\u2009=\u20090.644, 95% CI: 0.532\u20130.757,\n P<\/jats:italic>\n \u2009=\u20090.014) were valid tools to predict post-AMI NOAF. After\n Z<\/jats:italic>\n tests, the discriminatory performance of CA-125 was significantly higher than that of the CHA2DS2-VASc score (\n P<\/jats:italic>\n \u2009=\u20090.038), but not statistically significantly higher than that of the GRACE RS (\n P<\/jats:italic>\n \u2009=\u20090.353).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n An elevated plasma CA-125 level was independently associated with NOAF after AMI, with high discriminatory performance.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1718813","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:41Z","timestamp":1765175381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated plasma cancer antigen-125 level is associated with increased risk of new-onset atrial fibrillation after acute myocardial infarction"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuan","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1161\/CIRCULATIONAHA.110.986661","article-title":"Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis","volume":"123","author":"Jabre","year":"2011","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/hrt.2007.134486","article-title":"Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation","volume":"94","author":"Lopes","year":"2008","journal-title":"Heart"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e4483","DOI":"10.7759\/cureus.4483","article-title":"New-onset atrial fibrillation in patients presenting with acute myocardial infarction","volume":"11","author":"Iqbal","year":"2019","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.amjcard.2013.07.006","article-title":"New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry)","volume":"112","author":"Parashar","year":"2013","journal-title":"Am J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2147\/CIA.S166100","article-title":"Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHA2DS2-VASc scores","volume":"13","author":"Luo","year":"2018","journal-title":"Clin Interv Aging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/heartjnl-2016-310272","article-title":"Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women","volume":"103","author":"Sekiguchi","year":"2017","journal-title":"Heart"},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/AC.71.1.3132099","article-title":"Higher cancer antigen 125 level is associated with the presence of permanent atrial fibrillation in systolic heart failure patients","volume":"71","author":"Kaya","year":"2016","journal-title":"Acta Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00059-014-4148-4","article-title":"Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation","volume":"40","author":"Yucel","year":"2015","journal-title":"Herz"},{"key":"B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cca.2019.11.001","article-title":"Relationship between plasma cancer antigen (CA)-125 level and one-year recurrence of atrial fibrillation after catheter ablation","volume":"502","author":"Huang","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e042858","DOI":"10.1161\/JAHA.125.042858","article-title":"Identification of clinical phenotypes in type 2 myocardial infarction: insights into characteristics, prognosis, and management strategies","volume":"14","author":"Bertolini","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1050-1738(25)00099-4","DOI":"10.1016\/j.tcm.2025.07.007","article-title":"Gender and sex-related differences in type 2 myocardial infarction: the undervalued side of a neglected disease","author":"Angeli","year":"2025","journal-title":"Trends Cardiovasc Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.cjca.2018.09.015","article-title":"Accuracy of the Global Registry of Acute Coronary Events (GRACE) risk score in contemporary treatment of patients with acute coronary syndrome","volume":"34","author":"Shuvy","year":"2018","journal-title":"Can J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"Br Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5603\/CJ.a2014.0034","article-title":"Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: risk of new occurrence of atrial fibrillation and ischemic stroke","volume":"21","author":"Lau","year":"2014","journal-title":"Cardiol J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/biom.12107","article-title":"Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point","volume":"70","author":"Bantis","year":"2014","journal-title":"Biometrics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2015.10.013","article-title":"Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care","volume":"54","author":"Meulendijks","year":"2016","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00059-017-4598-6","article-title":"Association between BNP levels and new-onset atrial fibrillation: a propensity score approach","volume":"43","author":"Karabag","year":"2018","journal-title":"Herz"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.amjmed.2012.05.024","article-title":"Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome","volume":"125","author":"McManus","year":"2012","journal-title":"Am J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e15960","DOI":"10.1097\/MD.0000000000015960","article-title":"Clinical risk factors for new-onset atrial fibrillation in acute myocardial infarction: a systematic review and meta-analysis","volume":"98","author":"He","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.amjcard.2007.04.014","article-title":"Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction","volume":"100","author":"Aronson","year":"2007","journal-title":"Am J Cardiol"},{"key":"B25","first-page":"1075","article-title":"Serum tumor markers","volume":"68","author":"Perkins","year":"2003","journal-title":"Am Fam Physician"},{"key":"B26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jchf.2019.12.005","article-title":"Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis","volume":"8","author":"Nunez","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s00059-014-4109-y","article-title":"Clinical and prognostic value of elevated CA125 levels in patients with coronary heart disease","volume":"40","author":"Rong","year":"2015","journal-title":"Herz"},{"key":"B28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jchf.2014.01.005","article-title":"Is heart rate important for patients with heart failure in atrial fibrillation?","volume":"2","author":"Cullington","year":"2014","journal-title":"JACC Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/imj.12487","article-title":"Baseline characteristics and management of patients with atrial fibrillation\/flutter in the emergency department: results of a prospective, multicentre registry in China","volume":"44","author":"Zhang","year":"2014","journal-title":"Intern Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/eurheartj\/ehi350","article-title":"Inflammation in the genesis and perpetuation of atrial fibrillation","volume":"26","author":"Engelmann","year":"2005","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in acute myocardial infarction: the good, the bad and the ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/clc.20868","article-title":"Role of CA-125 in identification of right ventricular failure in chronic obstructive pulmonary disease","volume":"34","author":"Yilmaz","year":"2011","journal-title":"Clin Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2362.2011.02592.x","article-title":"Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation","volume":"42","author":"De Gennaro","year":"2011","journal-title":"Eur J Clin Investig"},{"key":"B34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.mehy.2012.05.042","article-title":"New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis","volume":"79","author":"Huang","year":"2012","journal-title":"Med Hypotheses"},{"key":"B35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/eurheartj\/ehq142","article-title":"Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure","volume":"31","author":"Nunez","year":"2010","journal-title":"Eur Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijcard.2008.11.172","article-title":"The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome","volume":"141","author":"Ozaydin","year":"2010","journal-title":"Int J Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"108861","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ehjcvp\/pvaf040","article-title":"Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials","volume":"11","author":"Fedele","year":"2025","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e47278","DOI":"10.7759\/cureus.47278","article-title":"The mysterious association between atrial fibrillation and cancer: a literature review","volume":"15","author":"Miqdad","year":"2023","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40256-024-00676-y","article-title":"Impact of newly diagnosed cancer on bleeding events in patients with atrial fibrillation treated with direct oral anticoagulants","volume":"24","author":"Angeli","year":"2024","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1718813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:42Z","timestamp":1765175382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1718813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":42,"alternative-id":["10.3389\/fcvm.2025.1718813"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1718813","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1718813"}}